Best Rising Stocks For 2014

BALTIMORE (Stockpickr) -- It's earnings season, and so far, the numbers are looking impressive. Out the gate, 70% of early reportingS&P 500 names have met or beat earnings expectations. But a whopping 78% of individual names in the big index are down over that same stretch, since earnings season started.

>>5 Toxic Stocks You Need to Sell in July

The clear takeaway is the earnings don't matter as much as most investors think -- at least not in their raw form.

But while the price direction from quarterly financial releases is far from obvious, earnings can certainly inject volatility into the marketplace. Last week was the fourth-biggest drop of 2014, and two of the other four took place during earnings season as well. Want to navigate the noise? Then focus on the "Rocket Stocks."

For the uninitiated, "Rocket Stocks" are our list of companies with short-term gain catalysts and longer-term growth potential. To find them, I run a weekly quantitative screen that seeks out stocks with a combination of analyst upgrades and positive earnings surprises to identify rising analyst expectations, a bullish signal for stocks in any market. After all, where analysts' expectations are increasing, institutional cash often follows. In the last 257 weeks, our weekly list of five plays has outperformed the S&P 500 by 79.51%.

Top 5 Forestry Stocks To Buy For 2015: WPCS International Incorporated(WPCS)

WPCS International Incorporated provides design-build engineering services for communications infrastructure. The company operates in three segments: Electrical Power, Wireless Communication, and Specialty Construction. The Electrical Power segment provides electrical contracting services to help commercial and industrial facilities for upgrading power systems; and creates integrated building systems, including the installation of structured cabling systems and electrical networks, as well as supports the integration of telecommunications, fire protection, security, and HVAC. The Wireless Communication segment designs and deploys wireless network solutions comprising Wi-Fi networks, point-to-point systems, mesh networks, microwave systems, cellular networks, in-building systems, and two-way communication systems. The Specialty Construction segment offers specialty construction services for building design, such as the design and integration of mechanical, electrical, hydra ulic, and life safety systems. The company provides its services to public services, healthcare, energy, and corporate enterprise markets worldwide. WPCS International Incorporated was founded in 1997 and is headquartered in Exton, Pennsylvania.

Advisors' Opinion:

• [By Monica Gerson]

  WPCS International (NASDAQ: WPCS) announced the public release of beta version of its Windows-based trading platform for bitcoin traders. WPCS shares jumped 26.49% to $1.91 in the after-hours trading.

• [By Ben Eisen]

  WPCS (WPCS) launched a beta version of BTX Trader, which is set to be used to gather data and execute trades on five exchanges for bitcoin, a virtual currency that has been highly volatile in recent weeks. Shares in WPCS were up 54% premarket.

• [By Wallace Witkowski]

  Shares of WPCS International Inc. (WPCS) �continued trading heavily after the bell Friday, a day when shares shot up nearly 68% to close at $2.53 after the launch of a trading platform for bitcoins. The day�� trading volume topped more than 1.5 million shares, more than triple its average regular session trading volume. Shares were down 3.2% at $2.45 after-hours at last check.

Best Rising Stocks For 2014: Alexandria Real Estate Equities Inc. (ARE)

Alexandria Real Estate Equities, Inc., a real estate investment trust (REIT), engages in the ownership, operation, management, development, acquisition, and redevelopment of properties for the life sciences industry. Its properties consist of buildings containing scientific research and development laboratories, and other improvements. The company offers its properties for lease primarily to universities and independent not-for-profit institutions; and pharmaceutical, biotechnology, medical device, life science product, service, biodefense, and translational research entities, as well as governmental agencies. As of December 31, 2006, it had 159 properties, including 156 properties located in 9 states in the United States and 3 properties located in Canada. As a REIT, the company is not subject to federal income tax to the extent that it distributes 100% of its taxable income to its stockholders. The company was founded in 1993 and is based in Pasadena, California.

Advisors' Opinion:

• [By Bill Stoller]

  After a banner 2013, the overall market has had a challenging start to 2014. However, these four companies have been crushing it: Alexander Real Estate (NYSE: ARE  ) , BioMed Realty Trust (NYSE: BMR  ) , CommonWealth REIT (NYSE: CWH  ) , and Sun Communities (NYSE: SUI  ) early on in 2014 vs. the S&P 500. Their relative out-performance can also be seen when compared to the Vanguard REIT Index ETF (NYSEMKT: VNQ  ) a good yardstick to measure sector performance.

Best Rising Stocks For 2014: Johnson Matthey PLC (JMAT)

Johnson Matthey Plc is a global specialty chemicals company operating in three divisions: Environmental Technologies, Precious Metal Products and Fine Chemicals. Environmental Technologies is a supplier of catalysts and related technologies for applications, such as pollution control, cleaner fuel, hydrocarbons and the hydrogen economy. Precious Metal Products��activities comprise the marketing, distribution, refining and recycling of platinum group metals (pgms), fabrication of products using precious metals and related materials, manufactures pgm and base metal catalysts and pgm chemicals. Fine Chemicals is a supplier of active pharmaceutical ingredients, fine chemicals and other specialty chemical products and services to chemical and pharmaceutical industry�� customer supplier of catalysts. In March 2012, Endo Pharmaceuticals Holdings Inc. acquired U.S. patent 7,851,482 B2 for oxymorphone hydrochloride from the Company. In March 2013, the Company acquired Formox AB. Advisors' Opinion:

• [By Sarah Jones]

  Barclays Plc (BARC) led a selloff by U.K. lenders as Sumitomo Mitsui Financial Group Inc. sold half of its stake in the bank. EasyJet Plc (EZJ) lost 4.1 percent as the carrier reported passenger numbers for May. Johnson Matthey Plc (JMAT) rallied 6.3 percent after posting pretax profit that beat analysts��estimates.

• [By Inyoung Hwang]

  Atos declined 3.5 percent after an investor cut its stake in the company. Intermediate Capital Group Plc lost 3.5 percent after Numis Securities Ltd. lowered its rating on the money manager. European Aeronautic, Defence & Space Co. slid 1.2 percent after UBS AG removed it from its recommended list of stocks. Johnson Matthey Plc (JMAT) climbed 3.6 percent after reporting a profit increase in the first half of the year.

• [By Sofia Horta e Costa]

  Barclays Plc (BARC) fell to a one-month low as Sumitomo Mitsui Banking Corp. sold a stake in the lender. Fiat SpA lost 6.5 percent as Chrysler Group LLC went in for a vehicle recall. France Telecom SA (FTE) rose after its Orange Business Services unit won a five-year deal to deploy a private network for Heineken NV. Johnson Matthey Plc (JMAT) jumped to its highest price in at least 23 years after posting full-year profit that beat estimates.

Best Rising Stocks For 2014: Hemispherx Biopharma Inc (HEB)

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. It has three subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp. The Company's foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A.

Ampligen

Ampligen is an experimental drug, which is undergoing clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Over 1,000 patients have participated in the Ampligen clinical trials representing the administration of more than 90,000 doses of this drug. The Company is also engaged in ongoing, experimental studies assessing the efficacy of Ampligen against influenza viruses.

Alferon N Injection

Alferon N Injection is the registered trademark for the Company's injectable formulation of natural alpha interferon. Interferons are a group of proteins produced and secreted by cells to combat diseases. The Company's natural alpha interferon is produced from human white blood cells. Alferon N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.

Alferon LDO (Low Dose Oral)

Alferon LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)]! is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon and like Alferon N Injection should not cause antibody formation, which is a problem with recombinant interferon. It is an experimental immunotherapeutic that works by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa.

The Company competes with Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta.

Advisors' Opinion:

• [By Matt Egan]

  Shares of Hemispherx Biopharma (HEB) soared 11% on Wednesday amid the rising Ebola fears. Earlier this week, the company announced a series of research collaborations aimed at developing treatments to fight Ebola.

• [By MONEYMORNING]

  Hemispherix Biopharma Inc. (NYSE: HEB) is a specialty pharmaceutical company. It engages in the clinical development of new drug therapies based on natural immune system enhancing technologies and targets the treatment of viral and immune-based clinical disorders. The Philadelphia, Pa.-headquartered company gained widespread attention over the last several months for its work on flu research. Its flagship products include Alferon N Injection, approved by the FDA for a category of sexually transmitted disease infection. Experimental treatments include Ampligen and Oragens, in development stages for the potential treatment of global viral diseases and disorders of the immune system including human papilloma virus, human immunodeficiency virus, chronic fatigue syndrome, hepatitis, and influenza. Shares have traded as low as $0.18 and as high as $0.55 over the last year. At last check, shares were changing hands around $0.50 on volume of 2 million shares.